A Six-Week Double-Blind Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial With Org 50081 in Patients With Chronic Primary Insomnia

Trial Profile

A Six-Week Double-Blind Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial With Org 50081 in Patients With Chronic Primary Insomnia

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Esmirtazapine (Primary)
  • Indications Insomnia
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPLETED
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 Apr 2013 Actual end date changed from Apr 2008 to Feb 2008 as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Additional lead trial centre and sponsor (Schering-Plough) identified as reported by ClinicalTrials.gov.
    • 21 Aug 2008 Actual number of patients added as 419 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top